Literature DB >> 8560188

HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self-antigens are dominated by closely related TCRBV gene segments. A study in patients with reactive arthritis.

R Duchmann1, E May, B Ackermann, B Goergen, K H Meyer zum Büschenfelde, E Märker-Hermann.   

Abstract

Identification of the T-cell receptors (TCR) used by synovial cytotoxic T lymphocytes (CTL) of patients with reactive arthritis (ReA) may be crucial to better understanding the pathogenetic mechanism underlying the HLA-B27 association of spondylarthropathies. The authors, therefore, sequenced 25 TCRB chains from HLA-B27-restricted CD8+ CTL clones and two clonal lines specific for self- or Yersinia enterocolitica antigen isolated from synovial fluids of 3 HLA-B27+ patients with ReA and PBL of one healthy HLA-B27+ individual. Fourteen non-HLA-B27-restricted CTL served as controls. Both autoreactive and Y. enterocolitica specific HLA-B27-restricted CTL used a highly limited set of VB genes with preferential rearrangement of three closely related VB families (VB 13, 14, 17), suggesting that these families contain a preferred site for contact with the HLA-B27 molecule. In addition, the presence of limited TCRBJ usage, limited heterogeneity in CDR3 sequences and dominant clones from individual donors among these CTL indicate that TCRB chain usage is further restricted by a limited set of peptides bound to the HLA-B27 molecule. Limited TCR usage by SF CTL of ReA patients may lay a basis for therapeutical manipulation of the T-cell response in the spondylarthropathies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8560188     DOI: 10.1046/j.1365-3083.1996.d01-16.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

Review 2.  Pathogenesis of reactive arthritis.

Authors:  J Sieper
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

3.  CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins.

Authors:  R Duchmann; C Lambert; E May; T Höhler; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

4.  Ankylosing spondylitis in monozygotic twins: studies on immunological parameters.

Authors:  T Höhler; R Hug; P M Schneider; F Krummenauer; C Gripenberg-Lerche; K Granfors; E Märker-Hermann
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

Review 5.  Pathways of cell activation in spondyloarthropathies.

Authors:  U Fearon; D J Veale
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 6.  T-cell studies in the spondyloarthropathies.

Authors:  E Märker-Hermann; P Schwab
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

Review 7.  The T cell receptor (TCR) in HLA-B27-restricted T cell responses--an introduction.

Authors:  E Märker-Hermann; R Duchmann; E May; B Ackermann; K H Meyer Zum Büschenfelde
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

8.  Analysis of T cell subsets present in the peripheral blood and synovial fluid of reactive arthritis patients.

Authors:  H Beacock-Sharp; J L Young; J S Gaston
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

9.  Clostridium difficile: an under-recognized cause of reactive arthritis?

Authors:  Julius Birnbaum; John G Bartlett; Allan C Gelber
Journal:  Clin Rheumatol       Date:  2007-09-28       Impact factor: 2.980

10.  HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides.

Authors:  E Frauendorf; H von Goessel; E May; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.